Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

AIMS: Addition of isatuximab (Isa) to pomalidomide/dexamethasone (Pd) significantly improved progression‐free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). We aimed to characterize the relationship between serum M‐protein kinetics and PFS in the phase 3 ICARIA‐MM trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298821/
https://www.ncbi.nlm.nih.gov/pubmed/34705283
http://dx.doi.org/10.1111/bcp.15123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298821/
https://www.ncbi.nlm.nih.gov/pubmed/34705283
http://dx.doi.org/10.1111/bcp.15123

Ejemplares similares